A phase IIa study to characterize the effects of CCL2 inhibition with the Spiegelmer NOX-E36 in patients with type 2 diabetes mellitus and albuminuria.
Latest Information Update: 21 Jul 2022
At a glance
- Drugs Emapticap pegol (Primary)
- Indications Diabetic nephropathies; Type 2 diabetes mellitus
- Focus Proof of concept; Therapeutic Use
- Sponsors NOXXON Pharma AG
- 01 Feb 2017 Results published in the Nephrology Dialysis Transplantation.
- 27 Apr 2016 Results published in the Nephrology Dialysis Transplantation
- 09 Jun 2015 Results presented at the 75th Annual Scientific Sessions of the American Diabetes Association.